Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

MLA

Weiss, Matthew M., et al. “Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.” Journal of Medicinal Chemistry, vol. 60, no. 14, July 2017, pp. 5969–89. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.6b01851.

APA

Weiss, M. M., Dineen, T. A., Marx, I. E., Altmann, S., Boezio, A., Bregman, H., Chu-Moyer, M., DiMauro, E. F., Feric Bojic, E., Foti, R. S., Hua Gao, Graceffa, R., Gunaydin, H., Guzman-Perez, A., Hongbing Huang, Liyue Huang, Jarosh, M., Kornecook, T., Kreiman, C. R., & Ligutti, J. (2017). Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. Journal of Medicinal Chemistry, 60(14), 5969–5989. https://doi.org/10.1021/acs.jmedchem.6b01851

Chicago

Weiss, Matthew M., Thomas A. Dineen, Isaac E. Marx, Steven Altmann, Alessandro Boezio, Howard Bregman, Margaret Chu-Moyer, et al. 2017. “Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.” Journal of Medicinal Chemistry 60 (14): 5969–89. doi:10.1021/acs.jmedchem.6b01851.